Ligand Pharmaceuticals Incorporated

NASDAQ
LGND
Stock
Yield per half year: -17.06%
Dividend yield: 0%
Sector: Healthcare

Share chart Ligand Pharmaceuticals Incorporated

Extended chart Simple chart
Financial Markets by TradingView

About Ligand Pharmaceuticals Incorporated

Ligand Pharmaceuticals Incorporated, a biopharmaceutical company, focuses on developing or acquiring technologies that help pharmaceutical companies to discover and develop medicines worldwide.

more details
Its commercial programs include Kyprolis and Evomela, which are used to treat multiple myeloma; Veklury for the treatment of moderate or severe COVID-19; Teriparatide injection product for osteoporosis; Vaxneuvance for the prevention of invasive disease caused by Streptococcus pneumoniae serotypes; and Pneumosil, a pneumococcal conjugate vaccine to help fight against pneumococcal pneumonia among children. The company also offers Rylaze, a recombinant erwinia asparaginase for the treatment of acute lymphoblastic leukemia or lymphoblastic lymphoma in adult and pediatric patients; Nexterone, a captisol-enabled formulation of amiodarone; and Zulresso, a captisol-enabled formulation of brexanolone for the treatment of postpartum depression. In addition, it provides Noxafil-IV, a captisol-enabled formulation of posaconazole for IV use; Duavee for the treatment of post-menopausal symptoms in women; Exemptia for autoimmune diseases; Vivitra for breast cancer; and Bryxta and Zybev for various indications. The company has alliances, licenses, and other business relationships with Amgen, Merck, Pfizer, Jazz, Takeda, Gilead Sciences, and Baxter International. Further, it sells Captisol materials. Ligand Pharmaceuticals Incorporated was incorporated in 1987 and is based in San Diego, California.
Add to compare list
Add to watchlist
Add to portfolio
Add to notification price

Main settings

IPO date 1992-11-18
ISIN US53220K5048
Industry Biotechnology
Sector Health Care
Валюта usd
Валюта отчета usd
Див.доход ао 0
Дивиденд ао 0.456
Сайт link
Цена ао 101.6
Change price per day: 0% (101.64)
Change price per week: -0.7906% (102.45)
Change price per month: -6.65% (108.88)
Change price per 3 month: -11.63% (115.01)
Change price per half year: -17.06% (122.55)
Change price per year: +19.65% (84.95)
Change price per 3 year: +22.18% (83.1899)
Change price per 5 year: +9.29% (93)
Change price per 10 year: +82.09% (55.82)
Change price per year to date: -10.35% (113.38)
All parameters

Grade

Underestimation
Title Value Grade
P/S 11.73 1
P/BV 2.36 6
P/E 24.35 6
EV/EBITDA 44.12 1
Total: 5.38
Efficiency
Title Value Grade
ROA, % -0.4664 0
ROE, % -0.5266 0
Total: 1.5
Dividends
Title Value Grade
Div yield, % 0 0
DSI 0.5 5
Total: 1.64
Debt
Title Value Grade
Debt/EBITDA 0.1655 10
Total: 10
Growth impulse
Title Value Grade
Yield Revenue, % -10.34 0
Yield Ebitda, % 34.19 5
Yield EPS, % 24.27 4
Total: 4.6
More

Main owners

Institutions Volume Share, %
Blackrock Inc. 2 962 314 16.73
Vanguard Group Inc 1 876 514 10.6
Janus Henderson Group PLC 1 343 154 7.59
Macquarie Group Limited 987 354 5.58
State Street Corporation 668 284 3.77
Dimensional Fund Advisors LP 661 298 3.74
Stephens Investment Management Group 659 434 3.72
St. Denis J. Villere & Company 428 051 2.42
Geode Capital Management, LLC 370 815 2.09
Pacer Advisors, INC. 325 727 1.84

Contained in ETF

ETFShare, %Profitability for 1 year, %Dividends, %
Syntax Stratified SmallCap ETF 0.3841 13.51 1.639
IndexIQ ETF Trust IQ U.S. Small Cap ETF 0.25 54.74 1.43
Future Tech ETF 0.1841 426.34 0.8416
Principal Healthcare Innovators ETF 0.1841 618.5 0.8416
iShares Morningstar Small-Cap Growth ETF 0.04601 595.05 0.72598
iShares Morningstar Small-Cap ETF 0.0404 391.25 1.60498
iShares Morningstar Small-Cap Value ETF 0.03432 187.77 2.50476
0.16326.741.37

Similar companies

P/E & P/BVEV/Ebitda & Debt/Ebitda


Company management

Head Job title Payment Year of birth
Mr. Matthew E. Korenberg President & COO 831.77k 1975 (50 years)
Mr. Octavio Espinoza Chief Financial Officer 613.59k 1971 (54 years)
Mr. Andrew T. Reardon J.D. Chief Legal Officer & Secretary 614.87k 1975 (50 years)
Mr. Todd Pettingill Director of Corporate Development N/A
Dr. Keith Marschke Senior Vice President of Biology & Scientific Affairs N/A
Dr. Vincent D. Antle Senior Vice President of Technical Operations & QA - Capitsol N/A 1969 (56 years)
Mr. Paul J. Hadden Senior Vice President of Investments & Business Development N/A
Mr. Patrick Lucy Senior VP & CBO Protein Expression Business N/A
Mr. Todd C. Davis Ph.D. CEO & Director 1961 (64 years)
Michael Jeong Head of Investor Relations

About company

Address: United States, San Diego. CA, 3911 Sorrento Valley Boulevard - Open in google maps, Open in yandex maps
Website: https://www.ligand.com